FDA Panel Rejects Lipocine's Testosterone Pill Post author:Sam Post published:January 10, 2018 Post category:BioPharma The FDA voted six in favor and thirteen against the benefit/risk profile of TLANDO. Source: BioSpace You Might Also Like FDA Grants New Clearance for NICO Corporation's Brain Surgery Technology January 31, 2017 AbbVie's PARP Inhibitor Fails to Deliver in Two Late-Stage Studies April 19, 2017 Egalet Reports First Quarter 2017 Financial Results May 9, 2017
